OKYO Pharma (NASDAQ:OKYO) Receives Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of OKYO Pharma (NASDAQ:OKYO) in a research note released on Tuesday morning, Benzinga reports. They currently have a $7.00 price objective on the stock.

OKYO Pharma Price Performance

Shares of NASDAQ:OKYO opened at $1.09 on Tuesday. The business’s 50 day simple moving average is $1.21 and its 200-day simple moving average is $1.36. OKYO Pharma has a 12 month low of $0.81 and a 12 month high of $3.07.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.